NorthStrive Biosciences Files Patent Applications for Obesity Treatment

NorthStrive Biosciences has filed two new U.S. patent applications focused on muscle preservation within the context of GLP-1 treatments and next-generation obesity therapies. This strategic move underscores the company's commitment to innovation in the rapidly expanding weight-loss drug market. By targeting muscle preservation, NorthStrive aims to address a key side effect of current treatments, potentially enhancing patient outcomes and differentiating its future offerings. The filings signal a proactive approach to securing intellectual property in a competitive therapeutic area.